Lecap Asset Management Ltd. Sells 33,030 Shares of Illumina, Inc. $ILMN

Key Points

• Lecap Asset Management Ltd. reduced its stake in Illumina, Inc. by 70.0%, selling 33,030 shares and maintaining 14,178 shares valued at approximately $1.35 million.
• Institutional investors own 89.42% of Illumina's stock, with several large investors increasing their shares during the first quarter.
• Illumina reported a quarterly EPS of $1.19, exceeding analyst expectations, despite a 4.8% decline in year-over-year revenue.

Lecap Asset Management Ltd. lowered its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 70.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,178 shares of the life sciences company's stock after selling 33,030 shares during the quarter. Lecap Asset Management Ltd.'s holdings in Illumina were worth $1,353,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Illumina by 3.5% in the 1st quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company's stock worth $1,298,928,000 after purchasing an additional 558,243 shares during the period. WCM Investment Management LLC boosted its position in shares of Illumina by 1.2% during the 1st quarter. WCM Investment Management LLC now owns 4,179,011 shares of the life sciences company's stock valued at $334,321,000 after acquiring an additional 49,156 shares during the last quarter. Corvex Management LP boosted its position in shares of Illumina by 125.2% during the 1st quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company's stock valued at $303,841,000 after acquiring an additional 2,129,449 shares during the last quarter. Brown Advisory Inc. boosted its position in shares of Illumina by 52.1% during the 1st quarter. Brown Advisory Inc. now owns 2,909,228 shares of the life sciences company's stock valued at $230,818,000 after acquiring an additional 996,589 shares during the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of Illumina by 361.7% during the 1st quarter. AQR Capital Management LLC now owns 2,121,585 shares of the life sciences company's stock valued at $165,484,000 after acquiring an additional 1,662,093 shares during the last quarter. Institutional investors own 89.42% of the company's stock.

Illumina Stock Performance

Shares of NASDAQ ILMN opened at $102.26 on Thursday. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The stock's 50-day moving average is $99.38 and its 200 day moving average is $89.64. The stock has a market cap of $15.72 billion, a price-to-earnings ratio of 12.94, a P/E/G ratio of 2.29 and a beta of 1.40. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. The business had revenue of $1.06 billion for the quarter, compared to analysts' expectations of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The business's quarterly revenue was down 4.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, sell-side analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the subject of a number of research analyst reports. Wall Street Zen downgraded Illumina from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Robert W. Baird lifted their price target on Illumina from $84.00 to $105.00 and gave the company a "neutral" rating in a research report on Monday, July 28th. Daiwa America downgraded Illumina from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 12th. Canaccord Genuity Group lifted their price target on Illumina from $99.00 to $105.00 and gave the company a "hold" rating in a research report on Friday, August 1st. Finally, Daiwa Capital Markets downgraded Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price target for the company. in a research report on Tuesday, August 12th. Six investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $123.06.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.